Considering multisystem manifestations of the underlying RASopathy in our child, including aggressive orbital rhabdomyosarcoma that was resistant to radiochemotherapy and required radical mutilating surgery, we chose MEK-inhibitor treatment with trametinib to modulate the general molecular pathogenetic mechanism from the HRAS genetic mosaicism. This evidence concerns the gene MAP2K7 and orbit rhabdomyosarcoma.